Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Expanding TKI Therapy in Advanced Lung Cancer

October 9th 2013

Amid rapid progress in the treatment of advanced lung cancer, several leading organizations have joined in developing new guidelines for the optimal use of molecular testing to help select patients for therapy with tyrosine kinase inhibitors

Dr. Langer on the Treatment of Early Stage Lung Cancer

October 8th 2013

Corey J. Langer, MD, professor of medicine, hematology/oncology division, University of Pennsylvania, Abramson Cancer Center, discusses the treatment of patients with early stage lung cancer.

Precision Cancer Medicine: New Era for Translating Lab Research Is Emerging

October 8th 2013

It is well recognized that advances in cancer management have most often resulted from a close collaboration between clinical and laboratory investigative efforts.

Verastem Targets Cancer Stem Cells

October 8th 2013

Cancer stem cells are an underlying cause of a tumor's ability to recur and metastasize even after initial treatment. Therefore, targeting those cancer stem cells could prove to be a valuable tool in the treatment of several different tumor types.

Dr. Camidge on AP26113 in Advanced Malignancies

October 7th 2013

D. Ross Camidge, MD, PhD, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies.

Lung Cancer in 2013: Where Are We?

October 4th 2013

Over the past year, there has been a multitude of exciting developments in the treatment of patients with non-small cell lung cancer

Dr. Carbone on Potential Biomarkers in Lung Cancer

October 3rd 2013

David P. Carbone, MD, PhD, a professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, discusses potential biomarkers in lung cancer.

Early Results Show Promise for Anti-PD-1 Antibody MK-3475 in NSCLC

October 2nd 2013

The investigational immunotherapy MK-3475 has demonstrated an objective response rate of up to 24% in patients with previously treated non-small cell lung cancer

Dr. CrinÃ² on Crizotinib in ALK-Positive NSCLC

October 1st 2013

Lucio CrinÃ², MD, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer

Dr. Camidge on a Phase I Study With AZD9291 in NSCLC

September 30th 2013

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses a phase I study looking at AZD9291 in patients with non-small cell lung cancer.

Novel ALK Inhibitor Shows Promise Against Brain Metastasis in NSCLC

September 30th 2013

The first-in-human phase I/II dose-finding study of a novel ALK/EGFR inhibitor called AP26113 demonstrated promising results in both crizotinib-resistant and crizotinib-naÃ¯ve patients with non-small cell lung cancer.

PD-L1 Inhibitor Delivers Rapid, Durable Responses in Advanced NSCLC

September 29th 2013

A phase I study has shown remarkable and durable responses with the engineered monoclonal antibody MPDL3280A in metastatic non-small cell lung cancer, including tumors with squamous and adenocarcinoma histology.

Dr. Novello on the Gray Areas in Lung Cancer Care

September 27th 2013

Silvia Novello, MD, PhD, assistant professor, Thoracic Oncology Unit, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses some of the "gray areas" that require more research for the treatment of patients with lung cancer.

Dr. Brahmer Discusses Managing Immunotherapy AEs

September 26th 2013

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the management of adverse events (AEs) from treatment with immunotherapies.

Dr. Pass on Blood-Based Markers in Lung Cancer

September 25th 2013

Harvey I. Pass, MD, Stephen E. Banner Professor of Thoracic Oncology, Vice-Chair Research, Department of Cardiothoracic Surgery, Division Chief, General Thoracic Surgery, NYU Langone Medical Center, discusses blood-based markers in lung cancer.

Dr. Scagliotti on Treating EGFR-Mutated Tumors with Afatinib

September 23rd 2013

Giorgio V. Scagliotti, MD, PhD, head, Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses treating epidermal growth factor receptor- (EGFR) mutated tumors with afatinib.

Chemotherapy Questions Linger in Early NSCLC

September 23rd 2013

The optimal use of adjuvant chemotherapy for patients with early-stage non-small cell lung cancer remains unresolved, with several clinical trials under way in Europe aimed at identifying ways to better select patients for treatment

Dr. Herbst on Targeting PD-1 and PD-L1 in Lung Cancer

September 19th 2013

Roy S. Herbst, MD, PhD, professor of Medicine at Yale Cancer Center and chief of Medical Oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses the differences of targeting PD-1 and PD-L1 when treating patients with lung cancer.

Learn More About Robotic Thoracic Surgery Offered at UC Davis

September 18th 2013

The section of General Thoracic Surgery at UC Davis is offering Robotic Thoracic Surgery to further enhance our top regional minimally invasive thoracic surgery program.

Dr. Bunn Discusses Afatinib in Lung Cancer

September 17th 2013

Paul A. Bunn, Jr, MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor (EGFR) mutation.